Piramal Pharma to release Q2 and H1 FY2026 results

Piramal Pharma Limited will hold a board of directors meeting on Wednesday, November 5, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025. The trading window for the company's securities, which closed on October 1, 2025, will remain shut until Friday, November 7, 2025.

Following the board meeting, the company will host a conference call for investors and analysts on Thursday, November 6, 2025, from 9:30 AM to 10:15 AM IST, to discuss its Q2 and H1 FY2026 results. Participants can join via designated dial-in numbers for India, USA, UK, Singapore, and Hong Kong, with an express join option available through prior registration.

Piramal Pharma Limited operates 17 global development and manufacturing facilities across over 100 countries, offering a diverse portfolio of products and services including contract development, critical care generics, and consumer healthcare products. The company also holds a strategic minority investment in Yapan Bio Private Limited, focusing on biologics/bio-therapeutics and vaccine segments.